Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Radiotherapy, Chemotherapy Claims Draw FDA “Courtesy” Letter

This article was originally published in The Tan Sheet

Executive Summary

Colin Worldwide is in compliance with FDA regulations after deleting certain claims for its Paecilomyces hepiali chen & Ganoderma nutritional supplement, the agency says in a June 3 letter

You may also be interested in...



“Dry Throat” Not A Disease, “Soothe” A Cosmetic Claim, Tom’s Of Maine Says

Tom's of Maine may not claim its eponymous Natural Bronchial Syrup for Children and Natural Bronchial Syrup for Adults "sooth[es] dry throat," FDA says in a recent "courtesy" letter

Earthmends Breast, Prostate Health Formula Claims Under FDA Review

The Cancer Wellness Institute's line of Earthmends Breast Health and Prostate Health dietary supplements will continue to carry claims they provide nutritional support for individuals undergoing cancer treatment or trying to prevent cancer, the Palm Harbor, Fla.-based company said.

People In Brief

Perrigo promotes in pricing, planning

Topics

UsernamePublicRestriction

Register

PS094427

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel